Current market catalysts

TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55

Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

Reported Earlier: 'HSBC to wind down German business for transaction services, over 300 jobs to be phased out' - Reuters

Bitcoin Holds $79,000, Defying Fed Hike Fears: What Is Going On?

Wintermute sees capital rotating from stalled stocks into crypto, with BTC resilient, ETF inflows strong, and $72,000 key support.

Signet CEO Says ‘Value’ Will Rule Holiday Shopping As Consumers Feel the Squeeze

Signet Jewelers (SIG) stock surges 19% on Q2 EPS beat, margin expansion, and a boosted FY27 outlook despite flat sales.

Why Is Strategy Stock Surging on Wednesday?

Strategy stock rose Wednesday alongside Bitcoin gains, a Canaccord Genuity price forecast raise to $179, and sold-out merchandise.

BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain

BridgeBio Pharma shares 52-week data on oral infigratinib for achondroplasia, showing improvements in sleep apnea, otitis media, and BMI.

Wells Fargo Maintains Overweight on ServiceTitan, Lowers Price Target to $105

TD Cowen Maintains Buy on ServiceTitan, Lowers Price Target to $100

HCA Healthcare CEO Says Guidance For Balance Of Year Does Not Assume A Rebound In Surgery

Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

TD Cowen Initiates Coverage On Faeth Therapeutics with Buy Rating

Wells Fargo Maintains Underweight on Paychex, Raises Price Target to $111

Here’s How Much You Would Have Made Owning Ciena Stock In The Last 15 Years

Ciena (NYSE:CIEN) has outperformed the market over the past 15 years by 10.87% on an annualized basis producing an average annual return of 23.91%. Currently, Ciena has a market capitalization of $48.17 billion. Buying

Wells Fargo Maintains Equal-Weight on Knife River, Lowers Price Target to $62

Argus Research Maintains Buy on Air Products, Raises Price Target to $329

From Burritos to Bulk Groceries: Uber Scales Delivery Reach with ShopRite Partner

Uber Eats expanded its grocery footprint across the Northeast by adding 375+ Wakefern supermarkets, including ShopRite and Fairway Market locations.

Wells Fargo Maintains Overweight on CRH, Lowers Price Target to $107

8-K filing — Barinthus Biotherapeutics plc. (BRNS)

Filed: 2026-09-09 AccNo: 0001104659-26-106183 Size: 272 KB Item 1.02: Termination of a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 9.01: Financial Statements and Exhibits

8-K filing — NorthWestern Energy Group, Inc. (NWE)

Filed: 2026-09-09 AccNo: 0001993004-26-000054 Size: 8 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Flotek Industries shares are trading higher after the company raised its FY2026 sales guidance above estimates.

These Analysts Revise Their Forecasts On Chime Financial

Chime will acquire Stride Bank for $590M, launch Chime Bank, and projects strong growth; shares rose 9.7% as analysts lifted price targets.

Smithfield Foods shares are trading lower after Barclays lowered its price target on the stock from $31 to $29.

Bernstein Maintains Market Perform on Vale, Raises Price Target to $12.5

Apple's 'Surprise and Shine' Moment Belongs to John Ternus

Apple’s first iPhone event under CEO John Ternus may unveil a foldable iPhone, higher Pro prices and a revamped Siri AI.

Uni-Fuels shares are trading higher after the company reported strong H1 financial results and raised its FY26 sales guidance above analyst estimates.

Oil Hits $100 a Barrel: Will Trump ‘TACO’ Again?

Brent crude is back above $100. Every prior run to triple digits this year ended with a US retreat — days before a Fed meeting that may hike.

Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65

Bernstein Maintains Outperform on Rio Tinto, Raises Price Target to $89.5

Evommune shares are trading lower after the company announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis. The experimental drug failed to reach both its primary and secondary endpoints across all tested dose levels, and the firm decided that it would not move EVO756 forward for atopic dermatitis.